ArticleJournal of experimental & clinical cancer research : CR2026
NHE7-Driven endoplasmic reticulum stress signaling transmission promotes malignant progression of endometrial cancer via c-Fos/PRSS1/ERP27 axis.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEndometrial cancer (EC) threatens women's health. The Na⁺/H⁺ Exchanger 7 (NHE7) is implicated in cancer progression, but its role in EC and potential link to endoplasmic reticulum (ER) stress remain poorly understood.
methodsNHE7 was overexpressed or knocked down in EC cells. Functional assays and transcriptomic analyses were performed. Supernatant (SN) or exosomes from donor EC cells were applied to recipient cells. Mechanistic studies included exosome inhibition (GW4869), bioinformatic analysis, dual-luciferase reporter assays, chromatin immunoprecipitation (ChIP), and ER stress manipulation (4-PBA/Tunicamycin). In vivo tumor models validated findings.
resultsNHE7 promoted malignant phenotypes, EMT, and stemness via ER stress activation. SN/exosomes from NHE7-overexpressing cells transmitted these phenotypes and ER stress to recipient cells, which were blocked by GW4869 or 4-PBA. PRSS1 was identified as a key NHE7 downstream target, and its exosomal delivery mediated ER stress transmission. Mechanistically, NHE7 drove PRSS1 transcription in donor cells via ER stress-dependent c-Fos recruitment to the PRSS1 promoter. In recipient cells, PRSS1 upregulated ERP27 to amplify ER stress. TCGA data showed that high PRSS1 expression correlated with poor prognosis. In vivo, NHE7 accelerated tumor growth and upregulated PRSS1/ERP27, effects reversed by 4-PBA.
conclusionNHE7 functions as a key regulator of ER stress signaling transmission in EC cells, driving malignant phenotypes and stemness through the c-Fos/PRSS1/ERP27 axis. Targeting this axis may offer a novel therapeutic strategy for EC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.